Breathe BioMedical
- Industry
- Medical Devices
- Founded Year
- 2005
- Headquarters
- 191 Halifax Street, Moncton, New Brunswick, Canada
- Employee Count
- 34
Key People
- William Dawes - Chief Executive Officer
- Peili Miao - Chief Financial Officer
- Christopher Purves - Chief Technology Officer
- Dr. Rachel Brem - Chief Medical Officer and Director
- Sandra Veenstra - Chief Regulatory Officer
- Joanne Young - Vice President, Clinical
- Jean Nadeau - Chairman of the Board
- Telfer Hanson - Vice Chairman of the Board
- Dr. Norman Betts - Director
- Romeo Goguen - Director
Assessment
- Team
-
Aspect: First-time 10+ yrs
Summary: The leadership team comprises experienced professionals with significant industry experience.
The executive team includes individuals with extensive backgrounds in medical technology and business management, enhancing the company's potential for success.
- Clinical Need
-
Aspect: Very Strong
Summary: The company's focus on early disease detection through breath analysis addresses a critical need in healthcare.
Early detection of diseases like cancer significantly improves treatment outcomes, making Breathe BioMedical's technology highly relevant and valuable.
- Competition
-
Aspect: Somewhat crowded
Summary: The market for non-invasive diagnostic tools is competitive, with several players developing similar technologies.
While Breathe BioMedical's technology is innovative, it faces competition from other companies in the non-invasive diagnostics space, which could impact market penetration.
- Technical Challenge
-
Aspect: Moderate
Summary: Developing accurate and reliable breath analysis technology presents moderate technical challenges.
Ensuring the sensitivity and specificity of breath-based diagnostics requires overcoming technical hurdles, but the company's progress indicates manageable challenges.
- Patent
-
Aspect: Strong
Summary: The company holds a strong patent portfolio, providing a competitive edge.
A robust patent portfolio protects the company's intellectual property and enhances its market position.
- Financing
-
Aspect: Medium
Summary: The company has secured moderate funding from various investors.
While the company has attracted investment, additional funding may be necessary to support ongoing research, development, and commercialization efforts.
- Regulatory
-
Aspect: Pivotal Trial
Summary: The company is in the process of conducting pivotal trials for its breath test technology.
Successful completion of pivotal trials is crucial for regulatory approval and market entry, representing a significant milestone for the company.
Opportunity Rollup
- Odds of Success
- 3.7
- Peak Market Share
- 5.1
- Segment CAGR
- 2.9%
- Market Segment
- Diagnostic Imaging
- Market Sub Segment
- Non-Invasive Diagnostics
| Year Post Launch | Market Penetration (%) |
|---|---|
| 1 | 0.26 |
| 2 | 0.76 |
| 3 | 1.78 |
| 4 | 3.57 |
| 5 | 5.10 |
Key Takeaway
Breathe BioMedical's innovative breath analysis technology addresses a critical need in early disease detection, offering significant market potential despite competitive and regulatory challenges.